AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025
AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October 17–21, 2025, unveiling an extensive lineup of new data across its diverse and industry-leading cancer portfolio. The company will present findings from more than 95 scientific abstracts, covering nine approved and nine investigational medicines, highlighting progress across multiple tumor types and treatment modalities.
Among these, two late-breaking presentations have been selected for Presidential Symposium sessions, underscoring the clinical significance of AstraZeneca’s latest research in breast, bladder, lung, prostate, gastric, and ovarian cancers. Additionally, the company will feature 26 oral presentations, including pivotal results from four major Phase III trials designed to redefine treatment paradigms in oncology.
Breakthrough Phase III Trials Spotlight AstraZeneca’s Vision for Redefining Cancer Care
Leading the ESMO 2025 presentations are several late-breaking and pivotal studies, including the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials evaluating Enhertu® (trastuzumab deruxtecan), and the TROPION-Breast02 Phase III trial of Datroway™ (datopotamab deruxtecan). These trials represent major milestones in AstraZeneca’s mission to reshape the treatment landscape for breast cancer.
- DESTINY-Breast11 (Abstract #291O, Presidential Symposium 1):
Evaluates Enhertu followed by paclitaxel, trastuzumab, and pertuzumab (THP) as neoadjuvant therapy for patients with high-risk, locally advanced HER2-positive early-stage breast cancer. - DESTINY-Breast05 (Abstract #LBA1, Presidential Symposium 1):
Investigates Enhertu as a post-neoadjuvant therapy for patients with HER2-positive early breast cancer at high risk of recurrence, comparing it with trastuzumab emtansine (T-DM1). - TROPION-Breast02 (Abstract #LBA21):
Examines Datroway as a first-line treatment for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) in patients who are not candidates for immunotherapy.
In addition to breast cancer, AstraZeneca will spotlight POTOMAC, a Phase III trial evaluating Imfinzi® (durvalumab) in combination with BCG therapy in non-muscle-invasive bladder cancer (NMIBC), and MATTERHORN, assessing perioperative Imfinzi with FLOT chemotherapy in patients with gastric and gastroesophageal junction (GEJ) cancers. Both trials will be featured in Proffered Paper sessions.
Executive Commentary: Driving the Next Wave of Innovation in Oncology
Dr. Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, emphasized the breadth of the company’s ESMO presentations:
We are advancing a broad portfolio of new treatments to transform patient care in breast cancer and sharing meaningful progress at ESMO with data from TROPION-Breast02, DESTINY-Breast11, and DESTINY-Breast05. Beyond breast cancer, our next wave of potential oncology medicines — including saruparib in prostate cancer, torvu-sam in ovarian cancer, and rilvegostomig in non-small cell lung cancer — reflect the scientific depth and ambition of our pipeline.”
Adding to this, Dave Fredrickson, Executive Vice President, Oncology Business Unit, stated:
The momentum of our oncology portfolio continues with presentations from four major pivotal trials at this year’s ESMO. Results from Enhertu and Datroway reinforce our leadership in antibody-drug conjugates, while POTOMAC demonstrates the potential of immunotherapy in early bladder cancer — aligning with our goal to bring novel treatments into early disease settings where they can make the greatest impact.”
Expanding Innovation Beyond Established Modalities
AstraZeneca’s research portfolio spans multiple scientific modalities, including antibody-drug conjugates (ADCs), immuno-oncology, DNA damage response (DDR) therapies, bispecific antibodies, and tumor driver-targeted therapies.
Key highlights across these areas include:
- FONTANA (Abstract #1065MO): First-in-human data from AZD5335, a folate receptor α (FRα)-targeting ADC, in platinum-resistant recurrent ovarian cancer.
- PETRANHA (Abstract #2384MO): Evaluating saruparib with androgen receptor pathway inhibitors in metastatic prostate cancer, marking the next evolution in DDR therapy.
- ARTEMIDE-01 (Abstract #1853MO): First data on rilvegostomig, a PD-1/TIGIT bispecific antibody, in checkpoint inhibitor-naïve metastatic NSCLC.
- FLAURA2 (Abstract #LBA77): Exploratory analysis of Tagrisso® (osimertinib) plus chemotherapy in EGFR-mutated advanced NSCLC, focused on patients with poor prognostic factors.
- CAPItello-281 (Abstract #2383O): Phase III results of Truqap™ (capivasertib) with abiraterone and ADT in PTEN-deficient metastatic hormone-sensitive prostate cancer.
- TROPION-PanTumor03 (Abstract #3072MO): First results of Datroway plus rilvegostomig in urothelial cancer, exploring combination ADC and immunotherapy approaches.
- BEGONIA (Abstract #555MO): Final data from Datroway plus Imfinzi in previously untreated metastatic TNBC, underscoring the synergy between ADCs and checkpoint inhibition.
Global Collaboration and Next-Generation Therapeutics
AstraZeneca continues to expand its global partnerships to accelerate oncology innovation. The company collaborates with Daiichi Sankyo on Enhertu and Datroway, with MSD (Merck & Co., Inc.) on Lynparza® (olaparib), and with HUTCHMED on Orpathys® (savolitinib).
Meanwhile, rilvegostomig, the company’s PD-1/TIGIT bispecific antibody, incorporates technology from Compugen’s clinical-stage anti-TIGIT antibody COM902, exemplifying AstraZeneca’s collaborative model of science-driven progress.
A Comprehensive Presence at ESMO 2025
AstraZeneca’s ESMO 2025 schedule features a robust lineup of presentations spanning antibody-drug conjugates, immuno-oncology, bispecific antibodies, tumor driver resistance mechanisms, and DNA damage response therapies.
Key late-breaking abstracts include:
- MATTERHORN (Abstract #LBA81): Final overall survival results of Imfinzi plus chemotherapy in gastric and GEJ cancers.
- POTOMAC (Abstract #LBA108): Imfinzi combined with BCG in non-muscle-invasive bladder cancer, potentially redefining standard care.
- RAMPART (Abstract #LBA93): Evaluating adjuvant durvalumab alone or with tremelimumab in resected renal cell carcinoma.
- DUO-O (Abstract #LBA44): Final overall survival from durvalumab plus paclitaxel/carboplatin/bevacizumab and olaparib maintenance in non-tBRCA-mutated ovarian cancer.
- HIMALAYA (Abstract #1494P): Updated efficacy and safety of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
The company will also highlight exploratory and biomarker-driven research, such as the SERENA-6 trial (camizestrant + CDK4/6 inhibitors in ER-positive breast cancer) and SAVANNAH, assessing Tagrisso plus Orpathys in MET-overexpressing NSCLC.
Redefining Cancer Treatment Through Precision and Early Intervention
AstraZeneca’s ESMO 2025 presentations reflect a strategic focus on targeted therapies, antibody-drug conjugates, and immune modulation, particularly in early disease settings. This aligns with the company’s overarching ambition to “redefine cancer care” — by preventing recurrence, extending survival, and improving quality of life across multiple tumor types.
By showcasing pivotal Phase III data and next-generation science at ESMO 2025, AstraZeneca underscores its role as a global leader committed to transforming oncology treatment through innovation, collaboration, and precision medicine.AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025
AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October 17–21, 2025, unveiling an extensive lineup of new data across its diverse and industry-leading cancer portfolio. The company will present findings from more than 95 scientific abstracts, covering nine approved and nine investigational medicines, highlighting progress across multiple tumor types and treatment modalities.
Among these, two late-breaking presentations have been selected for Presidential Symposium sessions, underscoring the clinical significance of AstraZeneca’s latest research in breast, bladder, lung, prostate, gastric, and ovarian cancers. Additionally, the company will feature 26 oral presentations, including pivotal results from four major Phase III trials designed to redefine treatment paradigms in oncology.
Breakthrough Phase III Trials Spotlight AstraZeneca’s Vision for Redefining Cancer Care
Leading the ESMO 2025 presentations are several late-breaking and pivotal studies, including the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials evaluating Enhertu® (trastuzumab deruxtecan), and the TROPION-Breast02 Phase III trial of Datroway™ (datopotamab deruxtecan). These trials represent major milestones in AstraZeneca’s mission to reshape the treatment landscape for breast cancer.
- DESTINY-Breast11 (Abstract #291O, Presidential Symposium 1):
Evaluates Enhertu followed by paclitaxel, trastuzumab, and pertuzumab (THP) as neoadjuvant therapy for patients with high-risk, locally advanced HER2-positive early-stage breast cancer. - DESTINY-Breast05 (Abstract #LBA1, Presidential Symposium 1):
Investigates Enhertu as a post-neoadjuvant therapy for patients with HER2-positive early breast cancer at high risk of recurrence, comparing it with trastuzumab emtansine (T-DM1). - TROPION-Breast02 (Abstract #LBA21):
Examines Datroway as a first-line treatment for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) in patients who are not candidates for immunotherapy.
In addition to breast cancer, AstraZeneca will spotlight POTOMAC, a Phase III trial evaluating Imfinzi® (durvalumab) in combination with BCG therapy in non-muscle-invasive bladder cancer (NMIBC), and MATTERHORN, assessing perioperative Imfinzi with FLOT chemotherapy in patients with gastric and gastroesophageal junction (GEJ) cancers. Both trials will be featured in Proffered Paper sessions.
Executive Commentary: Driving the Next Wave of Innovation in Oncology
Dr. Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, emphasized the breadth of the company’s ESMO presentations:
We are advancing a broad portfolio of new treatments to transform patient care in breast cancer and sharing meaningful progress at ESMO with data from TROPION-Breast02, DESTINY-Breast11, and DESTINY-Breast05. Beyond breast cancer, our next wave of potential oncology medicines — including saruparib in prostate cancer, torvu-sam in ovarian cancer, and rilvegostomig in non-small cell lung cancer — reflect the scientific depth and ambition of our pipeline.”
Adding to this, Dave Fredrickson, Executive Vice President, Oncology Business Unit, stated:
The momentum of our oncology portfolio continues with presentations from four major pivotal trials at this year’s ESMO. Results from Enhertu and Datroway reinforce our leadership in antibody-drug conjugates, while POTOMAC demonstrates the potential of immunotherapy in early bladder cancer — aligning with our goal to bring novel treatments into early disease settings where they can make the greatest impact.”
Expanding Innovation Beyond Established Modalities
AstraZeneca’s research portfolio spans multiple scientific modalities, including antibody-drug conjugates (ADCs), immuno-oncology, DNA damage response (DDR) therapies, bispecific antibodies, and tumor driver-targeted therapies.
Key highlights across these areas include:
- FONTANA (Abstract #1065MO): First-in-human data from AZD5335, a folate receptor α (FRα)-targeting ADC, in platinum-resistant recurrent ovarian cancer.
- PETRANHA (Abstract #2384MO): Evaluating saruparib with androgen receptor pathway inhibitors in metastatic prostate cancer, marking the next evolution in DDR therapy.
- ARTEMIDE-01 (Abstract #1853MO): First data on rilvegostomig, a PD-1/TIGIT bispecific antibody, in checkpoint inhibitor-naïve metastatic NSCLC.
- FLAURA2 (Abstract #LBA77): Exploratory analysis of Tagrisso® (osimertinib) plus chemotherapy in EGFR-mutated advanced NSCLC, focused on patients with poor prognostic factors.
- CAPItello-281 (Abstract #2383O): Phase III results of Truqap™ (capivasertib) with abiraterone and ADT in PTEN-deficient metastatic hormone-sensitive prostate cancer.
- TROPION-PanTumor03 (Abstract #3072MO): First results of Datroway plus rilvegostomig in urothelial cancer, exploring combination ADC and immunotherapy approaches.
- BEGONIA (Abstract #555MO): Final data from Datroway plus Imfinzi in previously untreated metastatic TNBC, underscoring the synergy between ADCs and checkpoint inhibition.
Global Collaboration and Next-Generation Therapeutics
AstraZeneca continues to expand its global partnerships to accelerate oncology innovation. The company collaborates with Daiichi Sankyo on Enhertu and Datroway, with MSD (Merck & Co., Inc.) on Lynparza® (olaparib), and with HUTCHMED on Orpathys® (savolitinib).
Meanwhile, rilvegostomig, the company’s PD-1/TIGIT bispecific antibody, incorporates technology from Compugen’s clinical-stage anti-TIGIT antibody COM902, exemplifying AstraZeneca’s collaborative model of science-driven progress.
A Comprehensive Presence at ESMO 2025
AstraZeneca’s ESMO 2025 schedule features a robust lineup of presentations spanning antibody-drug conjugates, immuno-oncology, bispecific antibodies, tumor driver resistance mechanisms, and DNA damage response therapies.
Key late-breaking abstracts include:
- MATTERHORN (Abstract #LBA81): Final overall survival results of Imfinzi plus chemotherapy in gastric and GEJ cancers.
- POTOMAC (Abstract #LBA108): Imfinzi combined with BCG in non-muscle-invasive bladder cancer, potentially redefining standard care.
- RAMPART (Abstract #LBA93): Evaluating adjuvant durvalumab alone or with tremelimumab in resected renal cell carcinoma.
- DUO-O (Abstract #LBA44): Final overall survival from durvalumab plus paclitaxel/carboplatin/bevacizumab and olaparib maintenance in non-tBRCA-mutated ovarian cancer.
- HIMALAYA (Abstract #1494P): Updated efficacy and safety of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
The company will also highlight exploratory and biomarker-driven research, such as the SERENA-6 trial (camizestrant + CDK4/6 inhibitors in ER-positive breast cancer) and SAVANNAH, assessing Tagrisso plus Orpathys in MET-overexpressing NSCLC.
Redefining Cancer Treatment Through Precision and Early Intervention
AstraZeneca’s ESMO 2025 presentations reflect a strategic focus on targeted therapies, antibody-drug conjugates, and immune modulation, particularly in early disease settings. This aligns with the company’s overarching ambition to “redefine cancer care” — by preventing recurrence, extending survival, and improving quality of life across multiple tumor types.
By showcasing pivotal Phase III data and next-generation science at ESMO 2025, AstraZeneca underscores its role as a global leader committed to transforming oncology treatment through innovation, collaboration, and precision medicine.AstraZeneca Showcases Transformative Oncology Pipeline with Breakthrough Data Across Multiple Cancer Types at ESMO 2025
AstraZeneca has reaffirmed its leadership in oncology innovation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, set to take place from October 17–21, 2025, unveiling an extensive lineup of new data across its diverse and industry-leading cancer portfolio. The company will present findings from more than 95 scientific abstracts, covering nine approved and nine investigational medicines, highlighting progress across multiple tumor types and treatment modalities.
Among these, two late-breaking presentations have been selected for Presidential Symposium sessions, underscoring the clinical significance of AstraZeneca’s latest research in breast, bladder, lung, prostate, gastric, and ovarian cancers. Additionally, the company will feature 26 oral presentations, including pivotal results from four major Phase III trials designed to redefine treatment paradigms in oncology.
Breakthrough Phase III Trials Spotlight AstraZeneca’s Vision for Redefining Cancer Care
Leading the ESMO 2025 presentations are several late-breaking and pivotal studies, including the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials evaluating Enhertu® (trastuzumab deruxtecan), and the TROPION-Breast02 Phase III trial of Datroway™ (datopotamab deruxtecan). These trials represent major milestones in AstraZeneca’s mission to reshape the treatment landscape for breast cancer.
- DESTINY-Breast11 (Abstract #291O, Presidential Symposium 1):
Evaluates Enhertu followed by paclitaxel, trastuzumab, and pertuzumab (THP) as neoadjuvant therapy for patients with high-risk, locally advanced HER2-positive early-stage breast cancer. - DESTINY-Breast05 (Abstract #LBA1, Presidential Symposium 1):
Investigates Enhertu as a post-neoadjuvant therapy for patients with HER2-positive early breast cancer at high risk of recurrence, comparing it with trastuzumab emtansine (T-DM1). - TROPION-Breast02 (Abstract #LBA21):
Examines Datroway as a first-line treatment for locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) in patients who are not candidates for immunotherapy.
In addition to breast cancer, AstraZeneca will spotlight POTOMAC, a Phase III trial evaluating Imfinzi® (durvalumab) in combination with BCG therapy in non-muscle-invasive bladder cancer (NMIBC), and MATTERHORN, assessing perioperative Imfinzi with FLOT chemotherapy in patients with gastric and gastroesophageal junction (GEJ) cancers. Both trials will be featured in Proffered Paper sessions.
Executive Commentary: Driving the Next Wave of Innovation in Oncology
Dr. Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, emphasized the breadth of the company’s ESMO presentations:
We are advancing a broad portfolio of new treatments to transform patient care in breast cancer and sharing meaningful progress at ESMO with data from TROPION-Breast02, DESTINY-Breast11, and DESTINY-Breast05. Beyond breast cancer, our next wave of potential oncology medicines — including saruparib in prostate cancer, torvu-sam in ovarian cancer, and rilvegostomig in non-small cell lung cancer — reflect the scientific depth and ambition of our pipeline.”
Adding to this, Dave Fredrickson, Executive Vice President, Oncology Business Unit, stated:
The momentum of our oncology portfolio continues with presentations from four major pivotal trials at this year’s ESMO. Results from Enhertu and Datroway reinforce our leadership in antibody-drug conjugates, while POTOMAC demonstrates the potential of immunotherapy in early bladder cancer — aligning with our goal to bring novel treatments into early disease settings where they can make the greatest impact.”
Expanding Innovation Beyond Established Modalities
AstraZeneca’s research portfolio spans multiple scientific modalities, including antibody-drug conjugates (ADCs), immuno-oncology, DNA damage response (DDR) therapies, bispecific antibodies, and tumor driver-targeted therapies.
Key highlights across these areas include:
- FONTANA (Abstract #1065MO): First-in-human data from AZD5335, a folate receptor α (FRα)-targeting ADC, in platinum-resistant recurrent ovarian cancer.
- PETRANHA (Abstract #2384MO): Evaluating saruparib with androgen receptor pathway inhibitors in metastatic prostate cancer, marking the next evolution in DDR therapy.
- ARTEMIDE-01 (Abstract #1853MO): First data on rilvegostomig, a PD-1/TIGIT bispecific antibody, in checkpoint inhibitor-naïve metastatic NSCLC.
- FLAURA2 (Abstract #LBA77): Exploratory analysis of Tagrisso® (osimertinib) plus chemotherapy in EGFR-mutated advanced NSCLC, focused on patients with poor prognostic factors.
- CAPItello-281 (Abstract #2383O): Phase III results of Truqap™ (capivasertib) with abiraterone and ADT in PTEN-deficient metastatic hormone-sensitive prostate cancer.
- TROPION-PanTumor03 (Abstract #3072MO): First results of Datroway plus rilvegostomig in urothelial cancer, exploring combination ADC and immunotherapy approaches.
- BEGONIA (Abstract #555MO): Final data from Datroway plus Imfinzi in previously untreated metastatic TNBC, underscoring the synergy between ADCs and checkpoint inhibition.
Global Collaboration and Next-Generation Therapeutics
AstraZeneca continues to expand its global partnerships to accelerate oncology innovation. The company collaborates with Daiichi Sankyo on Enhertu and Datroway, with MSD (Merck & Co., Inc.) on Lynparza® (olaparib), and with HUTCHMED on Orpathys® (savolitinib).
Meanwhile, rilvegostomig, the company’s PD-1/TIGIT bispecific antibody, incorporates technology from Compugen’s clinical-stage anti-TIGIT antibody COM902, exemplifying AstraZeneca’s collaborative model of science-driven progress.
A Comprehensive Presence at ESMO 2025
AstraZeneca’s ESMO 2025 schedule features a robust lineup of presentations spanning antibody-drug conjugates, immuno-oncology, bispecific antibodies, tumor driver resistance mechanisms, and DNA damage response therapies.
Key late-breaking abstracts include:
- MATTERHORN (Abstract #LBA81): Final overall survival results of Imfinzi plus chemotherapy in gastric and GEJ cancers.
- POTOMAC (Abstract #LBA108): Imfinzi combined with BCG in non-muscle-invasive bladder cancer, potentially redefining standard care.
- RAMPART (Abstract #LBA93): Evaluating adjuvant durvalumab alone or with tremelimumab in resected renal cell carcinoma.
- DUO-O (Abstract #LBA44): Final overall survival from durvalumab plus paclitaxel/carboplatin/bevacizumab and olaparib maintenance in non-tBRCA-mutated ovarian cancer.
- HIMALAYA (Abstract #1494P): Updated efficacy and safety of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
The company will also highlight exploratory and biomarker-driven research, such as the SERENA-6 trial (camizestrant + CDK4/6 inhibitors in ER-positive breast cancer) and SAVANNAH, assessing Tagrisso plus Orpathys in MET-overexpressing NSCLC.
Redefining Cancer Treatment Through Precision and Early Intervention
AstraZeneca’s ESMO 2025 presentations reflect a strategic focus on targeted therapies, antibody-drug conjugates, and immune modulation, particularly in early disease settings. This aligns with the company’s overarching ambition to “redefine cancer care” — by preventing recurrence, extending survival, and improving quality of life across multiple tumor types.
By showcasing pivotal Phase III data and next-generation science at ESMO 2025, AstraZeneca underscores its role as a global leader committed to transforming oncology treatment through innovation, collaboration, and precision medicine.
